Forward Pharma A/S (FWP) Given a $44.00 Price Target by Leerink Swann Analysts
Forward Pharma A/S (NASDAQ:FWP) received a $44.00 price objective from equities research analysts at Leerink Swann in a research report issued on Wednesday. The brokerage presently has a “buy” rating on the stock. Leerink Swann’s price target suggests a potential upside of 93.49% from the company’s previous close.
A number of other research firms also recently issued reports on FWP. Jefferies Group reiterated a “buy” rating on shares of Forward Pharma A/S in a report on Friday, September 2nd. Zacks Investment Research raised Forward Pharma A/S from a “sell” rating to a “hold” rating in a research report on Monday, August 22nd.
Forward Pharma A/S (NASDAQ:FWP) traded up 2.94% during midday trading on Wednesday, reaching $22.74. The company had a trading volume of 7,741 shares. Forward Pharma A/S has a 52-week low of $11.22 and a 52-week high of $24.09. The company’s 50-day moving average is $0.00 and its 200 day moving average is $0.00.
ILLEGAL ACTIVITY NOTICE: This report was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was illegally copied and republished in violation of international trademark & copyright legislation. The original version of this report can be accessed at https://www.thecerbatgem.com/2016/11/24/forward-pharma-as-fwp-given-buy-rating-at-leerink-swann.html.
A number of hedge funds and other institutional investors have recently modified their holdings of FWP. BlueMountain Capital Management LLC boosted its position in shares of Forward Pharma A/S by 21.9% in the first quarter. BlueMountain Capital Management LLC now owns 1,344,495 shares of the company’s stock valued at $22,856,000 after buying an additional 241,571 shares during the period. Perceptive Advisors LLC boosted its stake in Forward Pharma A/S by 67.1% in the second quarter. Perceptive Advisors LLC now owns 311,400 shares of the company’s stock worth $5,658,000 after buying an additional 125,100 shares during the last quarter. Motley Fool Wealth Management LLC boosted its stake in Forward Pharma A/S by 7.1% in the second quarter. Motley Fool Wealth Management LLC now owns 68,760 shares of the company’s stock worth $1,249,000 after buying an additional 4,529 shares during the last quarter. Sabby Management LLC boosted its stake in Forward Pharma A/S by 33.0% in the second quarter. Sabby Management LLC now owns 102,135 shares of the company’s stock worth $1,856,000 after buying an additional 25,350 shares during the last quarter. Finally, Morgan Stanley boosted its stake in Forward Pharma A/S by 123.4% in the third quarter. Morgan Stanley now owns 11,078 shares of the company’s stock worth $233,000 after buying an additional 6,120 shares during the last quarter. 22.62% of the stock is owned by hedge funds and other institutional investors.
About Forward Pharma A/S
Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.
Receive News & Stock Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related stocks with our FREE daily email newsletter.